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Background: The present study investigated human papillomavirus (HPV) prevalence in anal and urine
samples, and evaluated cytological ﬁndings among human immunodeﬁciency virus (HIV)-infected Jap-
anese men who have sex with men (MSM).
Methods: A total of 148 patients were enrolled. Anal and urine samples were collected from each
participant, and a HPV-DNA test and genotyping were performed using ﬂow-through hybridization. In
addition, anal cytology was evaluated based on Papanicolaou staining. Questionnaires regarding lifestyle
habits and sexual behavior were obtained.
Results: The b-globin gene was positive in 131 (88.5%) anal samples and 139 (94.0%) urine samples.
Among the b-globin-positive samples, the HPV prevalence in anal and urine samples was 80.9% and
30.9%, respectively. High-risk HPV (HR-HPV) was detected in 57.3% of anal samples and 20.9% of urine
samples. Among 122 adequate cytological samples, anal cytological abnormalities were observed in 99
cases (81.1%). Anal cytological tests revealed that atypical squamous cells of an undetermined signiﬁ-
cance (ASCUS) were detected in 57 (46.7%) patients, followed by low-grade squamous intraepithelial
lesions (SIL) in 35 (28.7%), high-grade SIL in ﬁve (4.1%), and atypical squamous cells cannot exclude high-
grade SIL (ASC-H) in two (1.6%), respectively. The nadir counts of CD4-positive T-lymphocyte less than
200 mL and anal HR-HPV infection were independent risk factors for anal cytological atypia over ASC-H.
Conclusions: The present study demonstrated high HPV prevalence in the anus and urine, and showed a
high incidence of anal cytological atypia associated with HR-HPV infections among HIV-infected MSM
patients.
© 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction immunodeﬁciency virus (HIV), and present HPV infections in theIt is widely accepted that human papillomavirus (HPV) is the
causative agent of cervical carcinoma inwomen. HPV can be passed
onto the genitals, oral cavity, throat, urinary tract, and anus be-
tween all individuals through sexual contacts, and it is the most
common pathogen of sexually transmitted infections (STIs). Men
who have sex with men (MSM) have a high risk for humanCancer Therapy and Urology,
an.
igehara).
d The Japanese Association for Infectioanus much more than men who have sex with women (MSW).
Some previous studies demonstrated that anal HPV prevalence
rates were 4e10 times higher in MSM compared to MSW [1,2]. In
particular, higher anal HPV infectious rates ranging from 47% to 96%
have been reported in HIV-infected MSM [3e9], which are higher
than ones reported in HIV-negative MSM [10,11]. Additionally, anal
cancer cases are strongly correlated with HPV infection. The inci-
dence of anal cancer is estimated to be 1.8 per 100,000 persons per
year in the general population, whereas the highest risk population
for anal cancer is HIV-infected MSM, among whom the incidence
has been estimated to be 30e100 times the general population
[10e12].us Diseases. Published by Elsevier Ltd. All rights reserved.
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anoscopy have been widely used for the detection of anal intra-
neoplasia (AIN), a precancerous anal lesion [13]. Anal cytological
abnormalities can be a predictor to anal dysplasia on histological
analysis of biopsy samples [14]; however, a formal recommenda-
tion to use a cytological evaluation as a screening procedure for
anal cancer for MSM has yet to be established. Further studies are
likely required to clarify the relationship between anal HPV infec-
tion, cytological abnormalities, and AIN among the high-risk MSM
population. Nevertheless, there is little information regarding anal
HPV prevalence, type, distribution, and anal cytological ﬁndings
within the MSM population in Japan.
In addition, some recent studies have suggested that the urinary
tract can also be alternative site for HPV infection among men in
addition to external genitalia and anus, and urine samples are used
as a convenient tool for testing HPV infections in the urinary tract
[15,16]. A broad range of HPV prevalence rate has been reported in
urine samples of healthy men and urethritis men [16e18]. However
few studies investigate HPV prevalence in urine among MSM
population.
Hence, the present study aimed to investigate anal HPV preva-
lence and cytological ﬁndings within the HIV-infected Japanese
MSM population. Additionally, we also investigated HPV preva-
lence in urine samples, and compared the HPV prevalence by anal
and urine samples. Furthermore, we aimed to identify the critical
factors affecting anal cytological abnormalities.
2. Patients and methods
2.1. Study population
The attending physicians recruited the Japanese HIV-infected
MSM patients that visited the outpatient clinic of Kanazawa Uni-
versity Hospital, Ishikawa Prefectural Central Hospital, and the
Shirakaba clinic, between April 2013 and August 2014, and a total of
148 patients enrolled in this study. All participants were MSM;
MSW, and bisexual men were excluded.
The ethics committee of Kanazawa University Graduate School
of Medical Science approved this study. Samples were collected
from each subject after each provided a written informed consent.
2.2. Sampling procedures
Anal samples were obtained by rubbing the entire surface of
anus and anal canal with a saline-wetted cotton swab, and were
placed into separate tubes containing 2.5 mL of a preservative so-
lution for liquid-based cytology (TACAS Amber; MBL Medical &
Biological Laboratories Co., Ltd.). In addition, urine samples were
provided in an individual urine cup, andwere placed into a separate
tube. Each urine sample (15 mL) was centrifuged at approximately
1500g for 10 min, and the supernatant was discarded. The urine
sediment was also placed into 2.5 mL of preservative solution for
liquid-based cytology. All preservative solution samples were
stored at 4 C until testing.
2.3. HPV-DNA test and genotyping
After vortexing each sample, aliquots of 600 mL of anal samples
and 800 mL of urine samples of the preservative solution containing
cell samples were centrifuged at approximately 1500g for 10 min,
and the supernatants were discarded. The cell pellets were washed
twice with 300 mL of 10 mmol/L Tris-HCI (pH 8.0). The DNA was
extracted from the cells using a DNA Extraction Kit (SMI Test; G&G
Science Co., Fukushima, Japan) according to the manufacturer'sinstructions. The b-globin gene was ﬁrst ampliﬁed to conﬁrm the
adequacy of the extracted DNA in all samples.
HPV genotyping was performed using the Hybribio 37 HPV
GenoArray Diagnostic Kit (HybriMax™; Chaozhou Hybribio
Limited Corporation, Guangzhou, China). This kit can determine 37
HPV genotypes, consisting of 15 high-risk HPV types (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82), 10 low-risk HPV types (6, 11,
42, 43, 44, 54, 61, 70, 72, 81), and 12 unknown-risk types (26, 34, 40,
53, 55, 57, 66, 67, 69, 71, 83, 84), by ﬂow-through hybridization and
gene-chip methods using HPV-DNA ampliﬁed by PCR [17,19].
2.4. Cytological evaluation for anal samples
Aliquots of 700 mL of each liquid-based cytological sample were
subjected tomicrotube centrifugation at 1500g for 10min and the
supernatants were discarded. The residual cell pellets were mixed
with 50 mL of a cellular base solution (LiquiPrep; LGM International
Inc, Melbourne, FL, USA), and pipetted onto glass microscope slides.
The slides were air-dried for more than 60 min and then subjected
to Papanicolaou staining. All slides were assessed by two cytopa-
thologists without previous knowledge of the molecular ﬁndings.
All slides were evaluated based on the Bethesda system as follows:
negative for an intraepithelial lesion ormalignancy (NILM), atypical
squamous cells of an undetermined signiﬁcance (ASCUS), and
atypical squamous cells that cannot exclude high-grade squamous
intraepithelial lesions (ASC-H), low-grade squamous intraepithelial
lesions (LSIL), and high-grade squamous intraepithelial lesions
(HSIL).
2.5. Collection of clinical data and questionnaire
We collected data on the age at examination, the status of the
HIV infection, nadir counts of CD4-positive T-lymphocytes, recent
counts of CD4-positive T-lymphocytes, the time since HIV diag-
nosis, the duration of antiretroviral therapy (ART) for HIV infection,
and recent HIV viral copies of all participants throughmedical chart
review. Lifestyle habits, sexual behavior, data on smoking status,
the past history of any genital warts, syphilis, urethritis, and the
period of the latest receptive anal intercourse (RAI) were examined
through patients' interviews from each attending physician. HIV-
positive cases were clinically conﬁrmed using the HIV-1/2 West-
ern blot assay (HIV Blot 2.2 WB; Gene labs Diagnostics, Singapore).
2.6. Statistical analyses
The chi-square test was used to compare HPV-positive rates
between the two anatomical sites among all 148 participants.
Univariate and multivariate analysis using unconditional direct
logistic regression analysis for all variables was performed to
determine the risk factors for cytological atypia over ASC-H in anal
samples, and the odds ratios (OR) and 95% conﬁdence intervals (CI)
were calculated. The SPSS statistical software package (version 17.0;
SPSS Inc., Chicago, IL) was used for all analyses, and a p < 0.05 was
taken to indicate statistical signiﬁcance.
3. Results
3.1. Patients characteristics
The mean age of the participants was 39.0 ± 8.0 years (range;
24e62 years). All of the patients had received ART. The time from
HIV diagnosis ranged from 509 to 6226 days (median 2000 days),
and the duration of ART therapy ranged from 290 to 5102 days
(median 1473 days). Mean (±standard deviation) of nadir and
recent counts of CD4-positive T-lymphocyte were 221 ± 101/mL
Table 2
Results of PCR analysis of adequate anal samples and urine samples by liquid-based
cytology.
Anal Urine p value
(n ¼ 131) (n ¼ 139)
Number of HPV detection (%) 106 (80.9%) 43 (30.9%) <0.001
High-risk HPV detection rate (%) 75 (57.3%) 29 (20.9%) <0.001
Multiple HPV detection rate (%) 68 (51.9%) 17 (12.2%) <0.001
PCR, polymerase chain reaction; HPV, human papillomavirus.
Table 3
Type-speciﬁc prevalence rates of HPV in anal and urine samples.
Detected HPV type Anus (n ¼ 106)
n (%)
Urine (n ¼ 43)
n (%)
High-risk HPV types
HPV 16 21 (19.8) 5 (11.6)
HPV 18 5 (4.7) 1 (2.3)
HPV 31 16 (15.1) 0
HPV 33 10 (9.4) 6 (14.0)
HPV 35 1 (0.9) 0
HPV 39 9 (8.4) 4 (9.3)
HPV 45 8 (7.5) 0
HPV 51 10 (9.4) 7 (19.2)
HPV 52 18 (17.0) 9 (20.9)
HPV 56 1 (0.9) 0
HPV 58 20 (18.9) 6 (14.0)
HPV 59 2 (1.9) 0
HPV 68 5 (4.7) 2 (4.7)
HPV 73 2 (1.9) 0
HPV 82 4 (3.8) 0
Low-risk HPV types
HPV 6 28 (26.4) 11 (25.6)
HPV 11 9 (8.4) 5 (11.6)
HPV 44 3 (2.8) 0
HPV 54 2 (1.9) 0
HPV 61 6 (5.7) 3 (7.0)
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tively. HIV viral load below 50 copies/mL of CD4-positive T-lym-
phocytes (suppressed state) was seen in 146 cases, whereas 50
copies/mL (unsuppressed state) was observed in 2 cases. More than
90% of patients experienced RAI in their lifetime, and more than
50% reported having RAI within last six months (Table 1). A few
patients (5.4%) had a history of urethritis.
3.2. HPV-DNA analyses
The b-globin gene was positive in 131 (88.5%) anal samples and
139 (93.9%) urine samples (Table 2). Among the b-globin-positive
samples, the HPV prevalence by anal and urine samples was 80.9%
and 30.9%, respectively. High-risk HPV (HR-HPV) was detected in
57.3% of anal samples and 20.9% of urine sample. Any HPV types and
HR-HPV prevalencewas signiﬁcantly higher in anal samples than in
urine samples (P < 0.05). Multiple HPV types were frequently
identiﬁed in anal samples (51.9%), whereas a single HPV-type
infection was more frequent (87.8%) in urine samples (P < 0.05).
Focusing on HPV type distributions, HPV6 was most common in
anal samples, followed by HPV16, HPV58, and HPV52. HPV6 was
also most common in urine samples, followed by HPV52, HPV51,
HPV33 and HPV58 (Table 3). HPV type distributions differed
slightly between the anus and urinary tract. Although 35 (35/148
cases; 23.6%) patients showed HPV infection in both anal and urine
samples, the detected HPV types were only partially consistent in
10 (10/148 cases; 6.8%) cases.
3.3. Cytological analyses
Cytological evaluation was performed in all 148 anal samples.
However, twenty-four anal samples were excluded for cytological
specimens due to classiﬁcation as unsatisfactory for evaluation. AllTable 1
Patient characteristics in HIV-infected MSM.
Variables N
Age (years)
Median ± SD (Range) 39.0 ± 8.0 (24e59)
Nadir counts of CD4þ T-lymphocyte (/ml)
Median ± SD (Range) 221.0 ± 101.0 (7e404)
Recent counts of CD4þ T-lymphocyte (/ml)
Median ± SD (Range) 593.0 ± 185.0 (167e1051)
Duration of ART (days)
Median ± SD (Range) 1472.5 ± 1029.7 (290e5102)
Time since HIV diagnosis (days)
Median ± SD (Range) 1999.5 ± 1240.8 (509e6226)
Recent HIV viral copies
Virally suppressed (<50 copies/ml) 146




Median ± SD (Range) 220.0 ± 278.0 (12e1280)
Past history of any genital warts
Yes/No 47/101
Past history of syphilis
Yes/No 66/82
Past history of urethritis
Yes/No 8/140
Time since recent RAI
<1 month 48
1e6 months 34




a Brinkman Index; number of cigarette smoking per day x duration (years); ART,
antiretroviral therapy; HIV, human immunodeﬁciency virus; RAI, receptive anal
intercourse.
HPV 70 5 (4.7) 2 (4.7)
HPV 72 5 (4.7) 0
HPV 81 12 (11.3) 1 (2.3)
Unknown -risk HPV types
HPV 34 1 (0.9) 0
HPV 53 7 (6.6) 0
HPV 55 1 (0.9) 0
HPV 57 1 (0.9) 2 (4.7)
HPV 66 3 (2.8) 1 (2.3)
HPV 69 3 (2.8) 0
HPV 71 5 (4.7) 1 (2.3)
HPV 83 2 (1.9) 0
HPV 84 6 (5.7) 1 (2.3)
HPV, human papillomavirus.of b-globin negative samples by the prior PCR-based analysis
included in these 24 samples, and the remaining samples had
positive expression of the b-globin gene. Twenty-three (23/122
cases; 18.9%) patients had NILM by liquid based cytological evalu-
ation. Any form of cytological abnormalities was observed in 99
cases (81.1%), with ASCUS the most commonly detected in 57
(46.7%) patients, followed by LSIL in 35 (28.7%), HSIL in 5 (4.1%),
ASC-H in 2 (1.6%), respectively (Table 4).3.4. Analyses of anal cytological abnormalities for identifying the
critical factors
The univariate and multivariate analysis showed that a nadir
count of CD4-positive T-lymphocytes lower than 200/mL (OR:
3.479; 95% CI: 1.500e8.068) and anal HR-HPV infection (OR: 2.562;
95% CI: 1.044e6.286) were independent risk factors for anal cyto-
logical atypia over ASC-H (Table 5). Conversely, age at examination,
Table 4
Frequency of detected HPV according to cytology results in anal samples.
Status of detected HPV Type of anal cytological atypia
NILM (%) ASCUS (%) ASC-H (%) LSIL (%) HSIL (%)
Any HPV types 14 (60.9) 45 (79.0) 2 (100) 29 (82.9) 5 (100)
High-risk HPV 9 (39.1) 30 (52.6) 2 (100) 23 (65.7) 4 (80.0)
Low-risk HPV 5 (21.7) 10 (17.5) 0 6 (17.1) 1 (20.0)
Total 23 (100) 57 (100) 2 (100) 35 (100) 5 (100)
HPV, human papillomavirus; NILM, negative for intraepithelial lesion or malignancy, ASCUS, atypical squamous cells of undetermined signiﬁcance; ASC-H, atypical squamous
cells cannot exclude high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
Table 5
Univariate and multivariate analyses of risk factors for anal cytological atypia greater than ASC-H.
Variables Univariate analysis Multivariate analysis
Odds ratio [95% CI] p value Odds ratio [95% CI] p value
HR-HPV infection in anusa 2.366 [1.031e5.429] 0.042 2.562 [1.044e6.286] 0.040
Age: >40 years old 1.424 [0.666e3.047] 0.362 e e
Past history of any genital warts 1.784 [0.826e3.857] 0.141 e e
Brinkman Index (>220) 0.609 [0.244e1.519] 0.287 e e
Past history of syphilis 1.093 [0.515e2.322] 0.816 e e
Past history of urethritis 0.740 [0.137e3.988] 0.726 e e
HPV infection in urine 0.642 [0.283e1.456] 0.289 e e
Nadir CD4þ T-lymphocyte counts: <200 mla 2.760 [1.254e6.073] 0.012 3.479 [1.500e8.068] 0.004
Recent CD4þ T-lymphocyte counts: <700 mL 0.861 [0.380e1.952] 0.720 e e
Latest period of RAI: 6 months 1.661 [0.729e3.783] 0.227 e e
ASC-H, atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion; HR, high-risk; HPV, human papillomavirus; RAI, receptive anal intercourse.
a Multivariate analysis.
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recent counts of CD4-positive T-lymphocyte lower than 600/mL,
latest RAI within six months, and HPV infection in urine samples
were not associated with anal cytological abnormalities.
4. Discussion
We found a high anal prevalence of HPV (80.9%) and HR-HPV
(57.3%) in the Japanese HIV-infected MSM population. Many
epidemiological studies have been conducted to investigate anal
HPV prevalence among HIV-infected MSM in several countries and
regions. Anal HPV prevalence in HPV-infected MSMwas 61.0% of 92
patients in the United States [3], 74.2% of 140 in Spain [4], 75.9% of
361 in Japan [5], 82.7% of 133 in Korea [6], 88.6% of 166 in Italy [7],
91.8% of 85 in South Africa [8], and 95.5% of 1439 in Spain [9]. The
high prevalence of anal HPV infection observed in the present study
is similar to that previously reported in other countries.
In addition, the present study revealed that the HPV infection
was detected in 30.9% of urine samples. A previous Japanese study
showed that HPV-DNA was detected in 21.0% of urine samples of
141 MSW with urethritis and in 3.3% of urine samples in 154
healthy men [16]. Nakashima et al. reported an HPV prevalence of
22.1% based on urine samples of 213 JapaneseMSWattending a STIs
clinic [18]. The HPV prevalence in urine samples of MSM in Japan
was much higher than ones in heterosexual men with urethritis or
healthy men. One previous study compared the HPV prevalence
between anal and urine samples among the HIV-infected MSM
population attending a clinical service in South Africa. HPV-DNA
was detected in 91.8% and 14.8% of anal and urine specimens,
respectively, in the study [8]. Another study demonstrated that HPV
prevalence in the rectum and urine of 113MSM attending a clinic in
France was 64% and 6%, respectively [20]. HPV prevalence in urine
samples in the present study was much higher than those reported
previously, which may be explained by differences in the popula-
tion, sexual activity, the HIV-infection status, and different sam-
pling procedures.A higher HPV prevalence in urine samples from the HPV-
infected MSM population raises an important issue: some clinical
studies and meta-analysis have indicated that HPV infection is
likely to have a certain etiological correlation with development of
urothelial carcinoma [15,21]. One previous report mentioned that
bladder cancers in HIV-infected patients may occur in relatively
young patients with a low nadir CD4 cell count [22], and suggested
that the HPV infection might be associated with bladder cancer
within HIV-infected patients [22]. The proportion of bladder cancer
is increased by at least 5-fold in HIV-infected patients above 50
years old [23]. However, little information regarding the incidence
of HPV-associated carcinomas of the urinary tract within the HIV-
infected MSM population is currently available. Therefore, further
studies are required to clarify a pathogenicity of urinary tract HPV
infections for the HIV-infected MSM population.
The most common HPV-types detected in the anus of HIV-
infected MSM were HPV6 and HPV16, which agrees with the
highest HPV genotype distribution reported previously in other
regions [7e9]. Conversely, HPV58 and 52, which are common type
in Japanese women, were considerably prevalent in the anus of the
Japanese MSM population. In addition to HPV6 and 16, HPV51 and
58were also relatively frequent in South Africa [8], HPV11 and 61 in
Italy [7], and HPV53 and 84 in Spain [9]. The distribution of HPV
types is likely to slightly differ between different regions and
populations. Furthermore, it is noteworthy that HPV16 was also a
frequent oncogenic HPV type detected in anal samples. Indeed,
many epidemiologic studies indicated that HPV16 is the most
common HPV type detected from HPV-associated anal carcinoma
[10,24].
We found that cytological abnormalities were observed in 81.1%
of anal samples, and that anal HR-HPV infection was identiﬁed as a
risk factor for anal cytological atypia higher grade than ASC-H. One
previous study examined a correlation between the cytological
ﬁndings and HR-HPV infection in the anus of 133 Korean MSM and
68 MSW; it was shown that 42.9% of the MSM presented abnormal
cytological ﬁndings in the anus, and it was signiﬁcantly higher in
H. Yaegashi et al. / J Infect Chemother 23 (2017) 621e626 625MSW [6]. The most common atypia was LSIL (22.6%), followed by
ASCUS (19.5%), and HSIL (0.8%). An epidemiological study con-
ducted in Spain among HPV-infected MSM revealed a high HR-HPV
prevalence (74.2%), and 54.2% of cytological atypia, such as LSIL
(49.2%), ASCUS (2.5%), and HSIL (2.5%) [4]. Wilkin et al. also found
that 47% of 85 HIV-infected men had abnormal results: LSIL (24%),
ASCUS (18%), and HSIL (6%) [3]. We found a higher rate of cyto-
logical abnormalities compared those reported previously, and that
ASCUS was the most frequent cytological abnormality. ASCUS is
deﬁned as a smear sample that reveals slightly abnormal squamous
cells, but the changes do not clearly suggest that precancerous cells
are present. Approximately 60% of the cases of ASCUS may be re-
classiﬁed as NILM, based upon alternative samples in cervical
cancer screening [25]. Indeed, HR-HPV was detected in only 52.6%
of cases with ASCUS, which lower than in cases of LSIL (65.7%) and
HSIL (80.0%). Alternatively, the improvement of recent diagnostic
techniques by liquid-based cytology may contribute to an increase
in ASCUS. Anal cytological atypia is likely to be frequently observed
in the HIV-infected MSM population with HR-HPV, and anal cancer
screening, such as HPV testing, and cytological evaluation should be
considered for this population.
There are numerous epidemiological studies that analyzed risk
factors for anal HPV infection amongMSM [2,6e8], whereas limited
information is available on predictors for anal cytological abnor-
malities. We found that a nadir count of CD4-positive T-lymphocyte
lower than 200 mL was an independent risk factor for anal cyto-
logical atypia. Consistent with our ﬁndings, a lower nadir of CD4-
positive T cells is an independent risk factor for cytological abnor-
malities and AIN [3,26,27]. However, recent counts of CD4-positive
T-lymphocyte were not associated with cytological atypia.
Previous reports suggest that HIV-infected patients with lower
nadir of CD4-positive cells may present with a decreased prolifer-
ative T cell response and to some types of immunosuppression
compared to those with a higher nadir of CD4-positive cells,
regardless of ART [10]. Immunosuppression can result in a persis-
tent anal HPV infection, inducing cytological atypia and AIN.
Furthermore in 2015, the World Health Organization recom-
mended that all HIV-infected patients should undergo induction of
ART, regardless of the CD4 count. An early induction of ART for HIV-
infected patients resulted in reduced morbidity and in the reduc-
tion of the incidences of HIV infection of their partners [28].
Considering that nadir CD4-positive cells can correlate to anal
cytological atypia, HIV-infected patients may beneﬁt from early
induction of ART.
However, there are some conﬂicting data regarding the effect of
CD4-positive T cells on anal cytological changes. Yamada et al.
demonstrated that not high-copy number of HIV amount but cur-
rent lower CD4-positive T cells is associated with higher grade
cervical lesions in Kenyanwomenwho had no ART [29].Wilkin et al.
reported that there was no association of current CD4-positive T
cells and nadir CD4-positive T cells with abnormal anal cytology or
high grade AIN [30]. Another previous study also found that HPV-
DNA detection as well as cytological abnormalities were associ-
ated neither with HIV RNA detection in plasma nor with CD4-
positive T cells [31]. Therefore, further studies, including large
population samples and of longitudinal design, are required to
clarify the risk factors associated with cytological abnormality by
HPV infection among HIV-positive population.
There are some limitations in the present study. This study
comprised a relatively small number of subjects and no HIV-
negative population or a MSW population. A relatively large pro-
portion of samples unsuitable for HPV testing and cytological
evaluation were included in this study. In addition, some data
regarding patients' background, including insertive or receptive
partners of anal intercourse and the use of condoms were notcollected. Additionally, the HPV type test used in the present study
is not common, although it has shown good agreement in detection
of HPV types compared to results by PCR-based methods [17,19].
Therefore, further studies should include a larger number of various
participants and use a common HPV genotyping method to support
the results of this study.
In conclusion, the present study found a high HPV prevalence in
urine and a high prevalence of anal cytological atypia associated
with HR-HPV infection in HIV-infected Japanese MSM. Currently,
HPV vaccination programs and anal cancer screening guidelines
have not been established in Japan, and HPV vaccination has been
interrupted, even in women due to potential adverse effects. To
prevent AIN and anal cancer among the MSM population, anal
cancer screening, such as HPV testing and cytology evaluation, may
need to be considered for MSM. Additionally, adaptation of the
prophylactic HPV vaccine for the MSM population should be also
discussed in Japan.Conﬂicts of interests
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